AstraZeneca Closes Acquisition of Amolyt Pharma


LYON, France and CAMBRIDGE, Mass., July 15, 2024 (GLOBE NEWSWIRE) -- Amolyt Pharma, a global, clinical-stage biopharmaceutical company specializing in developing therapeutic peptides for rare endocrine and related diseases, today announced that its previously announced acquisition by the global pharmaceutical company, AstraZeneca, has closed.

Read more:
AstraZeneca Closes Acquisition of Amolyt Pharma

Related Posts